Vip (vasoactive intestinal peptide) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Vip (vasoactive intestinal peptide) Rattus norvegicus
Analyze
Symbol: Vip
Name: vasoactive intestinal peptide
RGD ID: 621647
Description: Enables hormone activity. Involved in several processes, including negative regulation of smooth muscle cell proliferation; positive regulation of endothelial cell proliferation; and positive regulation of penile erection. Located in neuronal cell body. Used to study several diseases, including Parkinsonism; brain ischemia; periodontitis; pulmonary hypertension; and uveitis. Biomarker of visual epilepsy. Human ortholog(s) of this gene implicated in pulmonary sarcoidosis. Orthologous to human VIP (vasoactive intestinal peptide); INTERACTS WITH (S)-colchicine; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: vasoactive intestinal polypeptide; VIP peptides; vip/phi27
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8144,470,232 - 44,478,561 (+)NCBIGRCr8
mRatBN7.2142,064,878 - 42,073,219 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl142,065,120 - 42,073,216 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx142,603,576 - 42,611,659 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0148,590,772 - 48,598,855 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0142,679,038 - 42,687,121 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0142,169,307 - 42,177,582 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl142,169,501 - 42,177,582 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0143,498,288 - 43,506,465 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4136,361,513 - 36,369,594 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1136,365,863 - 36,372,520 (+)NCBI
Celera137,742,285 - 37,750,366 (+)NCBICelera
Cytogenetic Map1q11NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

References

References - curated
# Reference Title Reference Citation
1. Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Abad C, etal., Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19555-60. Epub 2010 Oct 26.
2. Differential involvement of hippocampal vasoactive intestinal peptide in nociception of rats with a model of depression. Belcheva I, etal., Peptides. 2009 Aug;30(8):1497-501. Epub 2009 May 23.
3. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. Camelo S, etal., J Ocul Pharmacol Ther. 2009 Feb;25(1):9-21.
4. The therapeutic effect of vasoactive intestinal peptide on experimental arthritis is associated with CD4+CD25+ T regulatory cells. Chen G, etal., Scand J Immunol. 2008 Dec;68(6):572-8.
5. Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis. Conlin VS, etal., Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G735-50. Epub 2009 Aug 6.
6. Differential regulation of vasoactive intestinal peptide (VIP) in the dentate gyrus and hippocampus via the NO-cGMP pathway following kainic acid-induced seizure in the rat. Cosgrave AS, etal., J Mol Neurosci. 2010 Nov;42(3):359-69. Epub 2010 Apr 6.
7. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Csati A, etal., Neuroscience. 2011 Nov 7.
8. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
9. Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats. Gurkan A, etal., J Periodontol. 2009 Oct;80(10):1655-64.
10. Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjogren's syndrome. Hauk V, etal., Clin Exp Immunol. 2011 Dec;166(3):309-16. doi: 10.1111/j.1365-2249.2011.04478.x.
11. VIP, CRF, and PACAP act at distinct receptors to elicit different cAMP/PKA dynamics in the neocortex. Hu E, etal., Cereb Cortex. 2011 Mar;21(3):708-18. Epub 2010 Aug 9.
12. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Ishihara T, etal., Neuron 1992 Apr;8(4):811-9.
13. Lateralized learning and memory effects of vasoactive intestinal peptide infused into the rat hippocampal CA1 area. Ivanova M, etal., Regul Pept. 2009 Aug 7;156(1-3):42-6. Epub 2009 May 22.
14. Inhibition of Toll-like receptor 4 with vasoactive intestinal peptide attenuates liver ischemia-reperfusion injury. Jiang W, etal., Transplant Proc. 2011 Jun;43(5):1462-7.
15. VIP and growth factors in the infected cornea. Jiang X, etal., Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6154-61. Print 2011 Aug.
16. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Jimeno R, etal., Immunol Cell Biol. 2010 Oct;88(7):734-45. Epub 2010 Mar 23.
17. Epithelial Expression of Vasoactive Intestinal Peptide in Ulcerative Colitis: Down-Regulation in Markedly Inflamed Colon. Jonsson M, etal., Dig Dis Sci. 2011 Dec 6.
18. Reduction in QSART and vasoactive intestinal polypeptide expression in the skin of Parkinson's disease patients and its relation to dyshidrosis. Kawada M, etal., J Cutan Pathol. 2009 May;36(5):517-21. Epub 2009 Mar 30.
19. Nerve fibers in uterosacral ligaments of women with deep infiltrating endometriosis. Kelm Junior AR, etal., J Reprod Immunol. 2008 Oct;79(1):93-9.
20. Role of Helicobacter pylori infection on neuronal expression in the stomach and spinal cord of a murine model. Li XB, etal., J Dig Dis. 2009 Nov;10(4):286-92.
21. Vasoactive intestinal peptide attenuates concanavalin A-mediated liver injury. Luo Q, etal., Eur J Pharmacol. 2009 Apr 1;607(1-3):226-33. Epub 2009 Feb 15.
22. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
23. Synaptic connections of distinct interneuronal subpopulations in the rat basolateral amygdalar nucleus. Muller JF, etal., J Comp Neurol 2003 Feb 10;456(3):217-36.
24. The vasoactive intestinal polypeptide (VIP) levels at the patients with ankylosing spondylitis and its association with inflammation markers. Nalbant S, etal., Rheumatol Int. 2011 Sep;31(9):1143-6. Epub 2010 Mar 26.
25. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
26. Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters. Nishimoto M, etal., Brain Res. 2011 Apr 6;1383:43-53. Epub 2011 Jan 31.
27. Nucleotide sequence divergence and functional constraint in VIP precursor mRNA evolution between human and rat. Nishizawa M, etal., FEBS Lett 1985 Apr 8;183(1):55-9.
28. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats. Onoue S, etal., Int J Pharm. 2011 May 30;410(1-2):54-60. Epub 2011 Mar 16.
29. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Prasse A, etal., Am J Respir Crit Care Med. 2010 Aug 15;182(4):540-8. Epub 2010 May 4.
30. GOA pipeline RGD automated data pipeline
31. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
32. Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy. Said SI and Hamidi SA, Pulm Circ. 2011 Jul;1(3):383-8.
33. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation. St Hilaire RC, etal., Peptides. 2010 Aug;31(8):1517-22. Epub 2010 May 7.
34. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Szema AM, etal., Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L880-6. Epub 2006 Jun 16.
35. Prevention of developmental delays in a Down syndrome mouse model. Toso L, etal., Obstet Gynecol. 2008 Dec;112(6):1242-51.
36. Antioxidant and Anti-Apoptotic Activity of Vasoactive Intestinal Peptide (VIP) Against 6-Hydroxy Dopamine Toxicity in the Rat Corpus Striatum. Tuncel N, etal., J Mol Neurosci. 2011 Aug 18.
37. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Tuncel N, etal., Peptides. 2005 May;26(5):827-36.
38. Molecular engineering of short half-life small peptides (VIP, alphaMSH and gamma3MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics. Vessillier S, etal., Ann Rheum Dis. 2012 Jan;71(1):143-9. Epub 2011 Oct 13.
39. VIP induces the translocation and degradation of the alpha subunit of Gs protein in rat pituitary GH4C1 cells. Yajima Y, etal., J Biochem. 1998 Jun;123(6):1024-30.
40. [Neuroprotective effects of vasoactive intestinal peptide against rat cerebral ischemia]. Yang J, etal., Nan Fang Yi Ke Da Xue Xue Bao. 2007 Dec;27(12):1801-4.
41. Vasoactive intestinal peptide in rats with focal cerebral ischemia enhances angiogenesis. Yang J, etal., Neuroscience. 2009 Jun 30;161(2):413-21. Epub 2009 Mar 28.
42. Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice. Yu R, etal., Peptides. 2011 Feb;32(2):216-22. Epub 2010 Dec 1.
43. Vasoactive intestinal polypeptide, an erectile neurotransmitter, improves erectile function more significantly in castrated rats than in normal rats. Zhang MG, etal., BJU Int. 2011 Aug;108(3):440-6. doi: 10.1111/j.1464-410X.2010.09901.x. Epub 2010 Dec 16.
44. Vasoactive intestinal polypeptide relaxes isolated rat pulmonary artery rings through two distinct mechanisms. Zhang S, etal., J Physiol Sci. 2010 Nov;60(6):389-97. Epub 2010 Aug 7.
45. [Effects of vasoactive intestinal peptide on Toll-like receptor (TLR) 2 mRNA and TLR4 mRNA expression on acute lung injury induced by lipopolysach aride in rat] Zuo WQ, etal., Zhonghua Er Ke Za Zhi. 2010 Jan;48(1):19-23.
Additional References at PubMed
PMID:1851524   PMID:2159586   PMID:3379062   PMID:8390245   PMID:8402943   PMID:12147214   PMID:12409220   PMID:12477932   PMID:12609771   PMID:12632517   PMID:12711712   PMID:12727330  
PMID:12960047   PMID:15033917   PMID:15040036   PMID:15050161   PMID:15344914   PMID:15467350   PMID:15561439   PMID:15627496   PMID:15716245   PMID:16328361   PMID:16469806   PMID:16564620  
PMID:16888155   PMID:16888191   PMID:16893891   PMID:17081520   PMID:17512547   PMID:17826907   PMID:17952636   PMID:18052688   PMID:18321609   PMID:18563302   PMID:18598846   PMID:18603306  
PMID:18810660   PMID:18829105   PMID:18835258   PMID:18992283   PMID:19220306   PMID:19661154   PMID:19945453   PMID:20074215   PMID:20688121   PMID:21061153   PMID:21620378   PMID:21725849  
PMID:21737879   PMID:22001490   PMID:22009726   PMID:22127604   PMID:22160165   PMID:24100601   PMID:24801739   PMID:25574088   PMID:25586379   PMID:25712659   PMID:25990439   PMID:30579677  
PMID:30817320   PMID:32212492   PMID:33098516   PMID:37119035   PMID:37218372   PMID:37646964  


Genomics

Comparative Map Data
Vip
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8144,470,232 - 44,478,561 (+)NCBIGRCr8
mRatBN7.2142,064,878 - 42,073,219 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl142,065,120 - 42,073,216 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx142,603,576 - 42,611,659 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0148,590,772 - 48,598,855 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0142,679,038 - 42,687,121 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0142,169,307 - 42,177,582 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl142,169,501 - 42,177,582 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0143,498,288 - 43,506,465 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4136,361,513 - 36,369,594 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1136,365,863 - 36,372,520 (+)NCBI
Celera137,742,285 - 37,750,366 (+)NCBICelera
Cytogenetic Map1q11NCBI
VIP
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh386152,750,797 - 152,759,760 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl6152,750,797 - 152,759,765 (+)EnsemblGRCh38hg38GRCh38
GRCh376153,071,932 - 153,080,895 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 366153,113,626 - 153,122,593 (+)NCBINCBI36Build 36hg18NCBI36
Build 346153,164,046 - 153,173,012NCBI
Celera6153,805,638 - 153,814,605 (+)NCBICelera
Cytogenetic Map6q25.2NCBI
HuRef6150,635,051 - 150,644,019 (+)NCBIHuRef
CHM1_16153,335,885 - 153,344,853 (+)NCBICHM1_1
T2T-CHM13v2.06153,952,118 - 153,961,081 (+)NCBIT2T-CHM13v2.0
Vip
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39105,589,131 - 5,597,617 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl105,589,218 - 5,597,617 (+)EnsemblGRCm39 Ensembl
GRCm38105,639,193 - 5,647,617 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl105,639,218 - 5,647,617 (+)EnsemblGRCm38mm10GRCm38
MGSCv37104,698,927 - 4,707,323 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36104,698,927 - 4,707,323 (-)NCBIMGSCv36mm8
Celera105,575,276 - 5,583,675 (+)NCBICelera
Cytogenetic Map10A1NCBI
cM Map101.97NCBI
Vip
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554399,021,904 - 9,031,792 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554399,021,923 - 9,031,783 (-)NCBIChiLan1.0ChiLan1.0
VIP
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v25172,771,030 - 172,780,044 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan16170,663,855 - 170,672,872 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v06150,564,545 - 150,573,582 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.16155,236,848 - 155,263,730 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl6155,254,652 - 155,263,730 (+)Ensemblpanpan1.1panPan2
VIP
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1142,941,655 - 42,950,160 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl142,941,224 - 42,950,700 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha143,780,582 - 43,789,690 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0143,121,172 - 43,130,243 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl143,121,202 - 43,130,243 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1142,993,230 - 43,002,341 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0142,856,855 - 42,865,968 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0143,344,732 - 43,353,814 (+)NCBIUU_Cfam_GSD_1.0
Vip
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024404946138,173,756 - 138,182,789 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049364895,425,726 - 5,434,785 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049364895,425,778 - 5,434,483 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
VIP
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl113,611,311 - 13,620,269 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1113,611,786 - 13,620,250 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2115,890,605 - 15,896,314 (+)NCBISscrofa10.2Sscrofa10.2susScr3
VIP
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.11380,217,602 - 80,228,320 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1380,218,572 - 80,228,278 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366604052,548,641 - 52,557,724 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Vip
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247855,468,563 - 5,488,143 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247855,466,429 - 5,487,763 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Vip
9 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:352
Count of miRNA genes:212
Interacting mature miRNAs:244
Transcripts:ENSRNOT00000025477
Prediction methods:Microtar, Miranda
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
738020Pia8Pristane induced arthritis QTL 84.7joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1165833076Rat
1578650Bmd6Bone mineral density QTL 612.2femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)150910843284926Rat
1578651Bmd7Bone mineral density QTL 714.2femur mineral mass (VT:0010011)compact volumetric bone mineral density (CMO:0001730)150910843284926Rat
1578669Bss9Bone structure and strength QTL 96.3femur morphology trait (VT:0000559)bone trabecular cross-sectional area (CMO:0002311)150910843284926Rat
1554320Bmd1Bone mineral density QTL 112.20.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)150910886060548Rat
1600360Mcs16Mammary carcinoma susceptibility QTL 162.4mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1224439043433040Rat
7421626Bp360Blood pressure QTL 3600.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1439328949393289Rat
631688Hcas2Hepatocarcinoma susceptibility QTL 230.0001liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)15925874115540829Rat
631508Sald1Serum aldosterone level QTL 13.7blood aldosterone amount (VT:0005346)serum aldosterone level (CMO:0000487)1985600154856001Rat
2302038Pia31Pristane induced arthritis QTL 315.50.001blood autoantibody amount (VT:0003725)serum immunoglobulin M-type rheumatoid factor level relative to an arbitrary reference serum (CMO:0002111)11099206555992065Rat
1300167Hrtrt2Heart rate QTL 24.35heart pumping trait (VT:2000009)heart rate (CMO:0000002)11148131275088344Rat
2313062Bmd73Bone mineral density QTL 733.90.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)11148131282174945Rat
2313065Bss67Bone structure and strength QTL 673.10.0001tibia area (VT:1000281)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313069Bss68Bone structure and strength QTL 682.90.0001tibia size trait (VT:0100001)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313075Bss66Bone structure and strength QTL 663.40.0001tibia length (VT:0004357)tibia length (CMO:0000450)11148131282174945Rat
2313077Bss69Bone structure and strength QTL 693.50.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)11148131282174945Rat
2313092Bmd72Bone mineral density QTL 722.50.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)11148131282174945Rat
2313097Bss70Bone structure and strength QTL 703.50.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
1578756Iddm22Insulin dependent diabetes mellitus QTL 222.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)11183518156835181Rat
5684998Bss101Bone structure and strength QTL 1013.6tibia strength trait (VT:1000284)tibia ultimate force (CMO:0001734)11543162149361612Rat
5684999Bss102Bone structure and strength QTL 1025.50.00000072tibia strength trait (VT:1000284)tibia stiffness (CMO:0001735)11543162149361612Rat
631494Bp95Blood pressure QTL 95400.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)11620621049268520Rat
634353Rends2Renal damage susceptibility QTL 20.05kidney blood vessel morphology trait (VT:0000530)organ lesion measurement (CMO:0000677)11933357156983283Rat
1558642Prcr2Prostate cancer resistance QTL 24.3prostate integrity trait (VT:0010571)area of ventral prostate occupied by tumorous lesions to total ventral prostate area ratio (CMO:0000899)12076315844095856Rat
724520Bp145Blood pressure QTL 1452.10.0024arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)12078482865784828Rat
1357397Bw41Body weight QTL 414.190.0001body mass (VT:0001259)body weight (CMO:0000012)12234064749361612Rat
1357401Bw43Body weight QTL 433.75body mass (VT:0001259)body weight (CMO:0000012)12234064749361612Rat
1357400Bw62Body weight QTL624.05inguinal fat pad mass (VT:0010424)inguinal fat pad weight to body weight ratio (CMO:0001253)12234064767340647Rat
631495Bp96Blood pressure QTL 964.52arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)122340647102268831Rat
1331785Rf27Renal function QTL 274.643urine sodium amount (VT:0006274)urine sodium level (CMO:0000129)12887978078430678Rat
1358359Sradr1Stress Responsive Adrenal Weight QTL 14.74adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)130882023123479925Rat
70225Bp58Blood pressure QTL 583.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132356093162846471Rat
1300172Bp172Blood pressure QTL 1723.56arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)13273727390665040Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132737458199368955Rat
1354599Bw29Body weight QTL 293.460.001body mass (VT:0001259)body weight (CMO:0000012)13344984878449848Rat
1354643Foco2Food consumption QTL 27.170.0001eating behavior trait (VT:0001431)food intake rate (CMO:0000427)13344984878449848Rat
8552900Pigfal1Plasma insulin-like growth factor 1 level QTL 17.4blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)13483685879836858Rat
8552948Pigfal11Plasma insulin-like growth factor 1 level QTL 114.7blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)13483685879836858Rat
9589820Insglur3Insulin/glucose ratio QTL 310.750.001blood insulin amount (VT:0001560)calculated plasma insulin level (CMO:0002170)13483685879836858Rat
1331732Srn4Serum renin concentration QTL 44.467renin activity (VT:0005581)plasma renin activity level (CMO:0000116)13523959878430678Rat
1331792Rf29Renal function QTL 294.589urine potassium amount (VT:0010539)urine potassium level (CMO:0000128)13523959878430678Rat

Markers in Region
RH130638  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2142,072,798 - 42,073,008 (+)MAPPERmRatBN7.2
Rnor_6.0142,177,162 - 42,177,371NCBIRnor6.0
Rnor_5.0143,506,045 - 43,506,254UniSTSRnor5.0
RGSC_v3.4136,369,174 - 36,369,383UniSTSRGSC3.4
Celera137,749,946 - 37,750,155UniSTS
Cytogenetic Map1p11UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 19
Low 4 8 25 2 5
Below cutoff 35 23 15 11 15 5 7 18 24 24 6 5

Sequence


RefSeq Acc Id: ENSRNOT00000025477   ⟹   ENSRNOP00000025477
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl142,065,120 - 42,073,216 (+)Ensembl
Rnor_6.0 Ensembl142,169,501 - 42,177,579 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000092791   ⟹   ENSRNOP00000076054
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl142,169,501 - 42,177,582 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000092879   ⟹   ENSRNOP00000076039
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl142,068,302 - 42,073,216 (+)Ensembl
Rnor_6.0 Ensembl142,170,281 - 42,177,581 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000093104   ⟹   ENSRNOP00000075997
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl142,066,220 - 42,073,216 (+)Ensembl
Rnor_6.0 Ensembl142,170,583 - 42,177,581 (+)Ensembl
RefSeq Acc Id: NM_053991   ⟹   NP_446443
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8144,470,480 - 44,478,561 (+)NCBI
mRatBN7.2142,065,138 - 42,073,219 (+)NCBI
Rnor_6.0142,169,501 - 42,177,582 (+)NCBI
Rnor_5.0143,498,288 - 43,506,465 (+)NCBI
RGSC_v3.4136,361,513 - 36,369,594 (+)RGD
Celera137,742,285 - 37,750,366 (+)RGD
Sequence:
RefSeq Acc Id: XM_017588691   ⟹   XP_017444180
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8144,470,298 - 44,478,561 (+)NCBI
mRatBN7.2142,064,949 - 42,073,219 (+)NCBI
Rnor_6.0142,169,363 - 42,177,582 (+)NCBI
Sequence:
RefSeq Acc Id: XM_017588692   ⟹   XP_017444181
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8144,470,271 - 44,478,561 (+)NCBI
mRatBN7.2142,064,906 - 42,073,219 (+)NCBI
Rnor_6.0142,169,307 - 42,177,582 (+)NCBI
Sequence:
RefSeq Acc Id: XM_039078200   ⟹   XP_038934128
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8144,470,232 - 44,478,561 (+)NCBI
mRatBN7.2142,064,878 - 42,073,219 (+)NCBI
RefSeq Acc Id: NP_446443   ⟸   NM_053991
- Peptide Label: preproprotein
- UniProtKB: Q9QUN1 (UniProtKB/Swiss-Prot),   P01283 (UniProtKB/Swiss-Prot),   A0A090BZQ0 (UniProtKB/TrEMBL),   A6KIN8 (UniProtKB/TrEMBL),   A0A1B0GWR8 (UniProtKB/TrEMBL),   A0A090AX27 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_017444181   ⟸   XM_017588692
- Peptide Label: isoform X1
- UniProtKB: B0BNF3 (UniProtKB/TrEMBL),   A0A1B0GWR8 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_017444180   ⟸   XM_017588691
- Peptide Label: isoform X2
- UniProtKB: A0A1B0GWR8 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000076039   ⟸   ENSRNOT00000092879
RefSeq Acc Id: ENSRNOP00000076054   ⟸   ENSRNOT00000092791
RefSeq Acc Id: ENSRNOP00000075997   ⟸   ENSRNOT00000093104
RefSeq Acc Id: ENSRNOP00000025477   ⟸   ENSRNOT00000025477
RefSeq Acc Id: XP_038934128   ⟸   XM_039078200
- Peptide Label: isoform X3
- UniProtKB: A0A1B0GWR8 (UniProtKB/TrEMBL)
Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P01283-F1-model_v2 AlphaFold P01283 1-170 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13689590
Promoter ID:EPDNEW_R115
Type:single initiation site
Name:Vip_1
Description:vasoactive intestinal peptide
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0142,169,483 - 42,169,543EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:621647 AgrOrtholog
BioCyc Gene G2FUF-61702 BioCyc
Ensembl Genes ENSRNOG00000018808 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ENSRNOG00055021671 UniProtKB/Swiss-Prot
  ENSRNOG00060008357 UniProtKB/Swiss-Prot
  ENSRNOG00065030773 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000025477 ENTREZGENE
  ENSRNOT00000025477.7 UniProtKB/Swiss-Prot
  ENSRNOT00000092879.2 UniProtKB/TrEMBL
  ENSRNOT00000093104.2 UniProtKB/TrEMBL
  ENSRNOT00055037126 UniProtKB/Swiss-Prot
  ENSRNOT00060013909 UniProtKB/Swiss-Prot
  ENSRNOT00065053062 UniProtKB/Swiss-Prot
Gene3D-CATH 6.10.250.590 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:7316540 IMAGE-MGC_LOAD
InterPro Glucagon_GIP_secretin_VIP UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VIP/GHRH-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:117064 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
MGC_CLONE MGC:188192 IMAGE-MGC_LOAD
NCBI Gene 117064 ENTREZGENE
PANTHER PTHR11213 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR11213:SF5 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Hormone_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Vip PhenoGen
PROSITE GLUCAGON UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000018808 RatGTEx
  ENSRNOG00055021671 RatGTEx
  ENSRNOG00060008357 RatGTEx
  ENSRNOG00065030773 RatGTEx
SMART GLUCA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A090AX27 ENTREZGENE, UniProtKB/TrEMBL
  A0A090BZQ0 ENTREZGENE, UniProtKB/TrEMBL
  A0A1B0GWR8 ENTREZGENE, UniProtKB/TrEMBL
  A0A8L2RDN4_RAT UniProtKB/TrEMBL
  A6KIN8 ENTREZGENE
  B0BNF3 ENTREZGENE, UniProtKB/TrEMBL
  P01283 ENTREZGENE
  Q9QUN1 ENTREZGENE
  VIP_RAT UniProtKB/Swiss-Prot
UniProt Secondary A6KIN8 UniProtKB/TrEMBL
  Q9QUN1 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2008-09-25 Vip  vasoactive intestinal peptide  Vip  vasoactive intestinal polypeptide  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2005-07-08 Vip  vasoactive intestinal polypeptide      Symbol and Name status set to approved 1299863 APPROVED
2002-08-07 Vip  vasoactive intestinal polypeptide      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_protein precursor protein contains both rat VIP and PHI-27 729982